[Cost analysis of the use of botulinum toxin type A in Spain.]

Conclusions: The appropriate BoNT-A choice would lead to considerablesavings for the National Health System. Botox® would generatelower costs per patient than other BoNT-A products in 9 out of 12 scenariosconsidered.
PMID: 24951903 [PubMed - as supplied by publisher]

Source: Farmacia Hospitalaria - June 22, 2014 Category: Drugs & Pharmacology Authors: De Andrés-Nogales F, Morell A, Aracil J, Torres C, Oyagüez I, Casado MA Tags: Farm Hosp Source Type: research